Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular and vascular penile ...

Unlike other phosphodiesterase-4 inhibitors on the market, PALI-2108 is a new chemical entity and is being administered to humans for the first time. To gain insights into the therapy’s effects ...

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

The cyclic nucleotide phosphodiesterase 4 (PDE4) regulates the hydrolysis ... However, none of the PDE4 inhibitors tested so far has reached the market, mainly owing to tolerability issues such ...

colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC). Palisade Bio presented a poster titled “PALI-2108, a Colon-Specific PDE4B ...

A new study reports that mirodenafil, a newly developed oral phosphodiesterase ... These improvements were noted after 4 weeks of treatment. The PDE5 inhibitor also resulted in a more marked ...